Shots:
- Voyager retains full rights to the vectorization technology and novel vectorized Abs emerges from the collaboration and has the right to pursue vectorized Ab programs targeting tau and alpha-synuclein alone or in collaboration with another partner
- As per collaboration agreements, Voyager has received an upfront payment to perform research and preclinical development of vectorized Abs directed against tau and alpha-synuclein in AD & PD respectively
- Voyager is not obligated to repay the upfront payment it received from AbbVie in connection with the Tau & ASN agreement but is no longer eligible to receive option payments, milestone payments, or royalties thereunder
Click here, Click here to read full press release/ article | Ref: Voyager | Image: PharmaShots
